Abstract

During the early phase of glucocorticoid (GC)-induced osteoporosis (GIO), GC increases the expression of receptor activator of NF-kappaB ligand (RANKL) in bone-forming cells and suppresses the production of interferon-beta in osteoclast progenitors, resulting in stimulation of bone resorption. On the other hand, GC represses the proliferation, differentiation and functional activities of bone forming cells, and finally induces their apoptosis throughout GIO, consequently causing the decrease in bone formation. In addition, as the number of bone-forming cells decrease, the osteoblast-dependent osteoclast formation also declines.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.